Monopril (Fosinopril Sodium)

Fosinopril, the active ingredient in Monopril, is an Angiotensin-Converting Enzyme (ACE) inhibitor presented as an oral dosage form for oral use. It is prescribed to lower elevated blood pressure and to improve outcomes in patients with heart failure. GNH USA supplies Monopril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fosinopril is an ACE‑inhibitor used in cardiovascular conditions that involve the renin‑angiotensin system.

Hypertension: reduces systolic and diastolic blood pressure to target levels. Heart failure: improves symptoms and decreases hospitalisation risk. Post‑myocardial infarction: helps prevent adverse cardiac remodeling and reduces mortality.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness: especially on standing (orthostatic). - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Hyperkalemia: elevated blood potassium levels. - Renal function changes: rise in serum creatinine.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure. - Acute renal failure: sudden loss of kidney function. - Hepatotoxicity: liver enzyme elevations. - Neutropenia: low white‑blood‑cell count. - Stevens‑Johnson syndrome: severe skin reaction.

Patients should be evaluated for specific risk factors before initiating therapy.

Pregnancy: contraindicated in the second and third trimesters (Category D). Renal impairment: monitor kidney function and adjust dose if needed. Hyperkalemia: avoid concomitant potassium‑sparing agents. Hypotension: assess volume status, especially after diuretic use. Drug monitoring: regular blood pressure and laboratory checks are recommended. Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Fosinopril may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of renal impairment and hyperkalemia. - Lithium: increased lithium levels leading to toxicity. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Diuretics: can potentiate hypotensive response, especially after first dose. - Antihyperglycemics: ACE inhibitors may enhance glucose‑lowering effect.